Iterum Therapeutics (NASDAQ:ITRM) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Iterum Therapeutics (NASDAQ:ITRM) from a hold rating to a buy rating in a report issued on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $0.75 target price on the stock.

According to Zacks, “Iterum Therapeutics plc is a clinical-stage pharmaceutical company. It develops and markets therapies to address unmet medical needs, as well as provides anti-infectives to treat multi-drug resistant pathogens. The company’s product pipeline consists of uncomplicated urinary tract infections, complicated urinary tract infections and complicated intra abdominal infections. Iterum Therapeutics plc is based in Dublin, Ireland. “

Other analysts have also recently issued research reports about the stock. Gabelli upgraded shares of Iterum Therapeutics from a sell rating to a hold rating and set a $0.70 target price for the company in a research note on Tuesday, July 27th. G.Research cut shares of Iterum Therapeutics from a hold rating to a sell rating in a research note on Friday, July 2nd. Finally, HC Wainwright cut shares of Iterum Therapeutics from a buy rating to a neutral rating and set a $0.69 target price for the company. in a research note on Monday, July 26th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus price target of $0.91.

Shares of ITRM stock opened at $0.60 on Tuesday. The stock has a market cap of $109.85 million, a P/E ratio of -0.36 and a beta of 1.22. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.80 and a quick ratio of 2.80. The company has a fifty day moving average price of $0.83 and a two-hundred day moving average price of $1.25. Iterum Therapeutics has a one year low of $0.45 and a one year high of $3.00.

Iterum Therapeutics (NASDAQ:ITRM) last posted its earnings results on Thursday, August 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. As a group, equities research analysts anticipate that Iterum Therapeutics will post -0.16 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. FineMark National Bank & Trust bought a new position in Iterum Therapeutics during the first quarter worth about $423,000. Grimes & Company Inc. increased its position in Iterum Therapeutics by 73.1% during the first quarter. Grimes & Company Inc. now owns 124,637 shares of the company’s stock worth $176,000 after acquiring an additional 52,637 shares during the period. HRT Financial LP increased its holdings in Iterum Therapeutics by 3,875.3% in the 1st quarter. HRT Financial LP now owns 399,479 shares of the company’s stock valued at $563,000 after buying an additional 389,430 shares during the period. Verition Fund Management LLC bought a new position in Iterum Therapeutics in the 1st quarter valued at about $159,000. Finally, UBS Group AG bought a new position in Iterum Therapeutics in the 1st quarter valued at about $75,000. 6.34% of the stock is currently owned by institutional investors and hedge funds.

About Iterum Therapeutics

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

See Also: Basic Economics creates winners and losers

Get a free copy of the Zacks research report on Iterum Therapeutics (ITRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.